Home Search

dbv - search results

If you're not happy with the results, please do another search
Viaskin Peanut

DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler Study

81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
Viaskin Peanut

DBV Outlines Path to Regulatory Approval of Viaskin Peanut Patch

0
Are Viaskin therapies finally on the horizon?
Viaskin-Patch

FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial to Commence

0
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in DBV Technologies

0
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

0
Another delay for the long-awaited therapy.
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in Children Ages 4-7

0
Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin Peanut in Peanut-Allergic...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Viaskin Patch

Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase 3 Trial

0
The patch therapy remains in regulatory limbo.
Viaskin Patch

DBV Optimistic Viaskin Peanut “Patch” Therapy has Path to Approval After FDA Feedback

0
DBV, which also has Viaskin therapies for milk and egg allergies in their pipeline, is encouraged by FDA feedback after denial of their peanut therapy.
DBV Patch Closeup

DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and Eggs, to Lay...

0
The company announced they would be laying off 200 employees in Q1.